Patents by Inventor Amandine Chefson

Amandine Chefson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
    Patent number: 12168657
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: December 17, 2024
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventors: Stéphane Dorich, Amandine Chefson
  • PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
    Publication number: 20240409540
    Abstract: The present disclosure relates to inhibitors of NLRP3 of Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Application
    Filed: August 9, 2024
    Publication date: December 12, 2024
    Inventors: Stéphane DORICH, Amandine CHEFSON, Stéphane CIBLAT
  • PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
    Publication number: 20240383896
    Abstract: The present disclosure relates to inhibitors of NLRP3 of Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 21, 2024
    Inventors: Stéphane DORICH, Amandine CHEFSON, Stéphane CIBLAT
  • COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF
    Publication number: 20240368160
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: July 3, 2024
    Publication date: November 7, 2024
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ
  • PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
    Publication number: 20240360130
    Abstract: The present disclosure relates to inhibitors of NLRP3 of Formula (I) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Application
    Filed: July 3, 2024
    Publication date: October 31, 2024
    Inventors: Stéphane DORICH, Amandine CHEFSON, Stéphane CIBLAT
  • PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3
    Publication number: 20240360129
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: July 3, 2024
    Publication date: October 31, 2024
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ, Ramsay BEVERIDGE, Stéphane CIBLAT
  • PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES
    Publication number: 20240360127
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Application
    Filed: July 3, 2024
    Publication date: October 31, 2024
    Inventors: Stéphane DORICH, Amandine CHEFSON
  • COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF
    Publication number: 20240360128
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: July 3, 2024
    Publication date: October 31, 2024
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ
  • PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3
    Publication number: 20240199606
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: October 3, 2023
    Publication date: June 20, 2024
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ, Ramsay BEVERIDGE, Stéphane CIBLAT
  • PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
    Publication number: 20240174661
    Abstract: The present disclosure relates to inhibitors of NLRP3 of Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopically labeled compound, or prodrug thereof, wherein Ring A is a 5- to 8-membered monocyclic heterocycloalkyl comprising at least one O ring atom, p is 0 or 1, and R1, R2, R3, R4, and X are as defined herein, useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Application
    Filed: March 27, 2023
    Publication date: May 30, 2024
    Inventors: Stéphane DORICH, Amandine CHEFSON, Stéphane CIBLAT
  • PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3
    Publication number: 20240174668
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: October 4, 2023
    Publication date: May 30, 2024
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ, Ramsay BEVERIDGE, Stéphane CIBLAT
  • COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF
    Publication number: 20240158396
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: December 11, 2023
    Publication date: May 16, 2024
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ
  • PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES
    Publication number: 20230303559
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Application
    Filed: November 9, 2022
    Publication date: September 28, 2023
    Inventors: Stéphane DORICH, Amandine CHEFSON
  • COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF
    Publication number: 20230159526
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: October 26, 2022
    Publication date: May 25, 2023
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ
  • COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF
    Publication number: 20220340567
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Application
    Filed: February 24, 2022
    Publication date: October 27, 2022
    Inventors: Stéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ
  • Compounds for inhibiting NLRP3 and uses thereof
    Patent number: 11319319
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: May 3, 2022
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventors: Stéphane Dorich, Amandine Chefson, Alexandre C{hacek over (o)}té